OncoMatch/Clinical Trials/NCT06897046

Perioperative Study of Iparomlimab and Tuvonralimab in Resectable NSCLC

Is NCT06897046 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including QL1706 and QL1706+Carboplatin+Paclitaxel（Albumin-bound ）/ Pemetrexed for non-small cell lung cancer (nsclc).

Phase 2RecruitingCancer Institute and Hospital, Chinese Academy of Medical SciencesNCT06897046Data as of May 2026

Treatment: QL1706 · QL1706+Carboplatin+Paclitaxel（Albumin-bound ）/ Pemetrexed — This project intends to study the efficacy and safety of Iparomlimab and Tuvonralimab with or without chemotherapyin the perioperative treatment of NSCLC

Check if I qualify

Extracted eligibility criteria

Cancer type

Non-Small Cell Lung Carcinoma

Biomarker criteria

Excluded: EGFR positive mutation

Presence of confirmed EGFR or ALK positive mutations

Excluded: ALK positive mutation

Presence of confirmed EGFR or ALK positive mutations

Disease stage

Required: Stage II, IIIA, IIIB (N2 ONLY) (AJCC 8th edition)

Stage II-IIIB (N2 only) non-small cell lung cancer (NSCLC) according to the 8th edition of the American Joint Committee on Cancer (AJCC). Only patients judged as T4 based on tumor size are allowed to be enrolled; other T4 conditions (e.g., invasion of the diaphragm, mediastinal involvement) are not permitted.

Performance status

ECOG 0–1(Restricted strenuous activity)

Prior therapy

No prior treatment (treatment-naive required)

Max 0 prior lines

Cannot have received: immune checkpoint inhibitor

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify